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Abstract
Background: Mitotic synchrony is the synchronous progression of a population of cells through the cell cycle and is
characteristic of non-diseased airway epithelial cells. However, we previously showed that asthmatic airway epithelial
cells are characterized by mitotic asynchrony and are pro-inflammatory as a result. Glucocorticoids can induce mitotic
synchrony that in turn suppresses the pro-inflammatory state of diseased cells, suggesting a novel anti-inflammatory
mechanism of action. Herein, we benchmarked traditional glucocorticoids against the ability of a new clinical-stage
dissociative steroidal drug, VBP15, for mitotic resynchronization and associated anti-inflammatory activity in asthmatic
airway epithelial cells.
Methods: Primary airway epithelial cells differentiated at air-liquid interface were exposed to VBP15, dexamethasone or
vehicle following in vitro mechanical injury. Basolateral cytokine secretions (TGF-β1, IL-6, IL-10, IL-13, and IL-1β) were
analyzed at different time points using cytometric bead assays and mitosis was examined by flow cytometry.
Results: VBP15 improved mitotic synchrony of proliferating asthmatic cells in air-liquid interface cultures compared to
vehicle-exposed cultures. VBP15 also significantly reduced the basolateral secretion of pro-inflammatory (i.e. IL-1β) and
pro-fibrogenic cytokines (i.e. TGF-β1) in air-liquid interface-differentiated asthmatic epithelial cultures following
mechanical injury.
Conclusion: VBP15 improves mitotic asynchrony and injury-induced pro-inflammatory and fibrogenic responses in
asthmatic airway epithelial cultures with efficacy comparable to traditional glucocorticoids. As it is predicted to show
superior side effect profiles compared to traditional glucocorticoids, VBP15 holds potential for treatment of asthma
and other respiratory conditions.
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Background
Glucocorticoids are well-established as a front-line ther-
apy in asthma. However, there are persistent concerns
about their long-term side-effects (e.g. growth failure in
children; adrenal suppression; weight gain) [1]. VBP15 is a
clinical-stage dissociative glucocorticoid identified as a
lead compound in a screening program focused on Δ-9,11
glucocorticoid-analogues that have potential as safer
alternatives to traditional glucocorticoids [2–5]. These
Δ-9,11 compounds are differentiated from glucocorti-
coids by the key conversion of a hydroxyl group to a
carbon-carbon double bond that retains transrepression
activities (NFκB inhibition), while reducing transactivation
activities (GRE-mediated gene transcription) [6]. VBP15
showed efficacy in mouse models of Duchenne muscular
dystrophy and multiple sclerosis while showing a much
reduced side effect profile when benchmarked against
prednisolone [2, 5].
In the context of asthma, we recently showed that oral
VBP15 abrogates pulmonary eosinophilia in murine
ovalbumin-induced allergic pneumonitis with comparable
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efficacy to the traditional glucocorticoid, prednisone [3].
These data suggest that VBP15 is an anti-inflammatory
alternative to traditional oral glucocorticoids for acute or
chronic asthma. However, immune-mediated inflamma-
tion is only one component of asthmatic inflammation.
Structural airway cells, such as epithelial cells, are also
important contributors to the pathogenesis of asthma [7].
In fact, we and others have shown that asthmatic
epithelium is intrinsically inflammatory via secretion
of cytokines [8, 9]. We further demonstrated that
asthmatic airway epithelial inflammation is secondary
to the abnormal mitotic behaviors of its regenerative
basal cell population [10]. Specifically, nonasthmatic air-
way epithelial basal cell populations progress in relative
synchrony through the cell cycle (G1, S, G2/M), while
asthmatic epithelial basal cells proliferate with a more
even distribution among the cell cycle phases (i.e. mitotic
asynchrony) [8, 10]. In other words, at any given time, the
majority of the epithelial progenitors in non-asthmatic air-
ways can be found in a single cell cycle phase. Whereas
asthmatic epithelial progenitors are distributed more
evenly through all of the cell cycle phases. This mitotic
asynchrony induces basolateral secretion of inflammatory
and fibrogenic cytokines. Using mitotic capture (i.e. pause
mitosis at a single checkpoint temporarily) with pulse-
exposure to a traditional glucocorticoid (i.e. dexame-
thasone), we resynchronized asthmatic epithelial mitosis,
thereby reducing the associated cytokine secretion [8, 10].
Herein we test the hypothesis that, similar to traditional
glucocorticoids, VBP15 also reduces asthmatic airway
epithelial-derived inflammation.
Methods
Cell culture and intermittent drug exposures
Non-asthmatic and asthmatic airway epithelial cells
(#AIR-606 and #AIR-606-Asthma; MatTek Corp., Ashland,
MA) were grown and differentiated at air-liquid interface
using previously described protocols [8, 11, 12]. Briefly,
these epithelial cells were proliferated on 6-well collagen-
coated Transwell membrane plates. The airway epithelial
cells were maintained at 37 °C for 7 days and then placed
at air-liquid interface with proprietary basolateral media
(provided by the manufacturer; MatTek Corp.) lacking
glucocorticoids and epidermal growth factor. Basolateral
media was replaced every 48 h for 21 days until the epithe-
lial cells differentiated as confirmed visually by microscopy.
After differentiation, the epithelial cultures were exposed
to VBP15 (n = 3), dexamethasone (DEX) (n = 6) or di-
methyl sulfoxide (DMSO) vehicle for 2 h at −26, −2, +22,
and +46 h. Cultures were mechanically scrape-wounded at
0 h and thereafter exposed continuously to bromo-
deoxyuridine (BrdU) to identify mitotically-active
cells, as further detailed below. All experiments were
determined to be exempt from the requirement of
Institutional Review Board review and approval under
United States Department of Health and Human Services
exemption 2 of section 46.101(b) of 45 Code of Federal
Regulations 46.
Mechanical injury model
A previously described in vitro airway epithelial injury
model for studying epithelial repair processes in the lung
was used in this study [8, 13–15] (Fig. 1). Briefly, using a
p1000 pipette tip, epithelial cultures were scraped in two
perpendicular lines at 0 h. The epithelial cultures were
then placed in BrdU-containing (10 μM) medium which
was replaced after a 2 h pulse of either VBP15 (10 μM),
DEX (20 nM), or DMSO vehicle at +24 h. Epithelial cul-
tures were incubated at 37 °C and 5 % CO2 until +48 h
after the injury. Cells were exposed to trypsin for 5 min at
37 °C and resuspended in trypsin neutralization solution
to obtain a single cell suspension.
Analysis of inflammatory mediators and cell cycle analysis
Cytometric bead arrays (BD Biosciences, San Jose, CA)
were used to measure inflammatory (IL-1β, IL-6, IL-10,
and IL-13) and fibrogenic (TGF-β1) cytokines in apical and
basolateral secretions at 0, +24, and +48 h. These cytokines
were selected as all, but IL-6, were significantly altered be-
tween asthmatic and non-asthmatic cultures in our prior
study [8]. Although we did not observe significant differ-
ences in IL-6 in that study, IL-6 levels trended higher in
the asthmatic cultures at many time points. Further, IL-6 is
receiving increasing attention as a potential mediator of
the marker of airway epithelial cell activation [16]. For
these reasons, we continue to include IL-6 in our standard
cytokine assays.
For cell cycle analyses, the cells were simultaneously la-
beled at +48 h with the following according to the manufac-
turers’ protocols: (1) Carboxyfluorescein FLICA Apoptosis
Poly-Caspase Detection Kit (Immunochemistry Technolo-
gies, LLC, Bloomington, MN) and (2) APC BrdU Flow Kit
containing 7-amino-actinomycin-D (BD Biosciences, San
Jose, CA). Data were analyzed using the cell cycle analysis
feature of FlowJo 7.6 (Tree Star, Inc., Ashland, OR).
Statistical analyses
Statistical comparisons were performed in SAS 9.3 soft-
ware (SAS Institute Inc., Cary, NC) using t-test functions
of log-transformed data within time points. Results are
reported as mean ± SEM unless otherwise noted. Signifi-
cance level was p ≤ 0.05.
Results
VBP15 improves mitotic synchrony in asthmatic human
airway epithelium
We first examined the effects of VBP15 in restoring mi-
totic synchrony during the regenerative phase in asthmatic
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airway epithelial cell cultures. In these experiments,
human airway epithelial cells underwent mechanical in-
jury (wounding) as previously described [8], and then were
harvested into single-cell suspensions at +48 h for flow cy-
tometry to characterize cellular distribution in G1/G0, S,
and G2/M, focusing on cells incorporating BrdU. Of note,
there was no significant difference in level of BrdU incorp-
oration between the VBP15 and DEX culture conditions
for wounded asthmatic epithelial cultures (mean ± SEM:
0.10 ± 0.04 % versus 0.10 ± 0.04 % of total cells; P = 0.91).
Mitosis in non-asthmatic wounded airway epithelial
cultures was synchronous (e.g. >70 % of cells in G1/G0)
and unaltered by the administration of DEX. In contrast,
wounded asthmatic epithelial cultures exhibited mitotic
asynchrony relative to non-asthmatic control cultures
(G1/G0, S, G2/M: 47 ± 0, 21 ± 2, 33 ± 2 % for asthmatic
airway epithelial cells vs. 71 ± 1, c-asthmatic airway
epithelial cells; Fig. 2). Mitotic synchrony was im-
proved in wounded asthmatic airway epithelial cul-
tures exposed to VBP15 (59 ± 4, 17 ± 1, 24 ± 3 %), but
not to the same degree as DEX (74 ± 3, 8 ± 3, 18 ±
0 %).
VBP15 reduces post-wounding asthmatic epithelial
basolateral inflammatory and fibrogenic secretions
Given the observed beneficial effect of VBP15 on epithelial
mitotic synchrony, we next tested whether VBP15 also ab-
rogates post-wounding asthmatic epithelial basolateral in-
flammatory and fibrogenic cytokine secretions (i.e. IL-1β,
IL-6, IL-10, IL-13 and TGF-β1). Previous studies have
shown that these cytokines play an important role in asth-
matic inflammation and airway remodeling [17]. Consist-
ent with our previous experiments, human asthmatic





















Fig. 1 Experimental design for in vitro wounding of airway epithelial cultures: Epithelia were pulsed for two hours every 24 h with 20nM
dexamethasone (DEX), 10 μM VBP15 (VBP), or vehicle (VEH) at the times shown. Mechanical scrape-wounding occurred at zero hours with
continuous BrdU exposure until cell harvest at +48 h for cytokine and mitotic analyses. Media samples were frozen before measurement of
inflammatory cytokines
Fig. 2 VBP15 Improves Mitotic Asynchrony in Asthmatic Human Airway Epithelia: Compared with wounded non-asthmatic epithelial cultures,
wounded asthmatic epithelial cultures at +48 h showed a more even distribution of BrdU+ cells among the cell cycle phases (i.e., G1/G0, S, and
G2/M) consistent with mitotic asynchrony (Left Panel). Pulse exposures of asthmatic epithelial cultures to VBP15 improved cell cycle synchrony as
shown by normalization of the percentage of mitotic cells in each cell cycle phase although to a lesser extent than for dexamethasone
(DEX)-exposed epithelial cultures. Statistical comparisons of the percentage of BrdU+ cells in G1/G0 among conditions are shown (Right
Panel). Experiments were conducted in triplicate in N = 3 donors per group. (*p < 0.05 vs. normal vehicle, #p < 0.05 vs. asthma vehicle)
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cytokines following wounding relative to non-asthmatic
preparations. DEX pulses altered the secretion of various
inflammatory and fibrogenic cytokines (reduced TGF-β1
and IL-13; increased IL-10) in a similar manner to our
previously published results [8].
There were similarities and differences between DEX
and VBP15 in terms of effects on basolateral cytokine
secretion. Similar to DEX, VBP15 reduced TGF-β1 se-
cretion by approximately 80 % at +24 h and 95 % at +48 h
(p < 0.05; Fig. 33). As well, IL-13 secretion was reduced
approximately 50 % at +48 h by DEX and by VBP15, al-
most to zero. In addition, VBP15 significantly reduced the
secretion of IL-10, IL-6, and IL-1β while DEX increased
their secretion (i.e. IL-10) or had no effect (i.e. IL-6, IL-
1β). Baseline values of cytokines were consistent with ve-
hicle control values which remained unchanged through
the course of the experiment.
Discussion
There is a critical need to develop new asthma medica-
tions that retain the highly beneficial action of traditional
glucocorticoids, but without the deleterious effects of their
long-term use [1]. Herein, we studied VBP15, a novel
Δ-9,11 glucocorticoid-analogue that optimizes several
activities of traditional glucocorticoids while minimizing
side effects [2–5], in an in vitro model of human airway
epithelia lacking immune cells. Our results are the first to
demonstrate that VBP15 improves mitotic asynchrony
and inflammatory/fibrogenic cytokine secretion in asth-
matic human airway epithelial cells.
VBP15 is a dissociative glucocorticoid identified as a
lead compound in a screening program focused on Δ-9,11
glucocorticoid-analogues [2–5]. VBP15 possesses a mo-
lecular modification in the 9,11 position of the traditional
glucocorticoid ring structure which results in dissociation
of glucocorticoid-mediated anti-inflammatory signaling
(transrepression, NFκB inhibition), from glucocorticoid-
receptor-mediated transcriptional activity and subsequent
side-effects (transactivation) [2–4]. We have recently
confirmed that VBP15 exhibits robust in vivo anti-
inflammatory activity mediated by inhibition of NFκB
activation that is at least as potent as that seen with
traditional glucocorticoids [2, 3]. We have also shown
that this mechanism occurs independently of glucocortic-
oid response element (GRE) activation (transactivation),
or upregulation of inhibitory transcripts [2]. As GRE-
regulated genes have been implicated in traditional gluco-
corticoid deleterious effects, including osteopenia, stunted
growth and adrenal suppression, Δ-9,11 glucocorticoid-
analogues are particularly promising because they provide
a clear approach to improve traditional glucocorticoid side
effect profiles.
We have recently reported that VBP15-mediated inhib-
ition of NFκB is sufficient to retain the anti-inflammatory
activity of conventional glucocorticoids [2]. Importantly,
despite the lack of GRE-mediated transcriptional proper-
ties, systemic VBP15 treatment is at least as effective as
prednisolone, a traditional glucocorticoid treatment, at re-
ducing pulmonary NFκB activity, leukocyte degranulation,
+22 to 24 +46 to 48

















Fig. 3 VBP15 effectively reduces post-wounding asthmatic epithelial
basolateral inflammatory secretions: Levels of cytokines measured by
cytometric bead assay are shown for basolateral secretions from
asthmatic and non-asthmatic human airway epithelial cells differentiated
at air-liquid interface. Measurements were obtained post-injury at
+24, and +48 h. Data are shown as mean ± SEM in pg/mL and
significance was obtained by t-test using corresponding time points
for DMSO vehicle (VEH)-exposed, DEX-exposed, and VBP15-exposed
asthmatic cultures. Experiments were conducted in triplicate using N =
3 donors. (*p < 0.05 vs. vehicle, #p < 0.05 vs. DEX)
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and the release of Th2 pro-inflammatory cytokines
(i.e. IL-13) in the lungs of a murine model of ovalbumin-
induced allergic asthma [3]. Moreover, VBP15 treat-
ment does not result in stunting of growth [2, 3]—a
major known side-effect of glucocorticoids in child-
hood asthma [1].
Initial experiments evaluated whether VBP15 restores
mitotic synchrony in ALI-differentiated asthmatic airway
epithelial cell cultures. This is a relevant question for the
asthmatic condition because epithelial mitotic asyn-
chrony is an important biological feature of the disease
[8, 10, 18]. Importantly, similar to the effects seen with
the traditional glucocorticoid, dexamethasone, VBP15
improved epithelial mitosis in asthmatic airway epithelial
cells and promoted appropriate airway epithelial mitotic
synchrony after mechanical injury. The latter findings
may be connected to our recent data demonstrating that
VBP15 has beneficial physicochemical effects on the
plasma membrane, protecting cells from injury and pro-
moting membrane repair [2].
Extended experiments in asthmatic airway epithelial
cells exposed to VBP15 identified that the intrinsic
secretion of inflammatory and fibrogenic cytokines was
abrogated by VBP15 to an even greater degree than
dexamethasone. In concert with the apparently better
mitotic synchrony-inducing effect of dexamethasone,
this raises the possibility of a threshold effect rather than
a linear dose–response between mitotic synchrony and
cytokine secretion. In addition, IL-10 was actually de-
creased by VBP15 in these experiments even though
dexamethasone increases the expression of this import-
ant anti-inflammatory cytokine. This supports the need
for future investigation as to whether the beneficial re-
ductions in pro-inflammatory cytokines outweigh poten-
tially harmful reductions in anti-inflammatory cytokines.
This study is an initial step to examine the possible
therapeutic actions of VBP15 on the human respiratory
epithelium, a potential target for the treatment of asthma,
and we acknowledge several limitations. Although we
used three different human airway epithelial donors, there
is still the possibility of significant heterogeneity among
the individuals with regard to asthma phenotype, treat-
ment regimens and severity of disease at the time of tissue
availability. In addition, our data do not directly acknow-
ledge the long term remodeling consequences implicated
by our model as they show the relation between inflam-
mation and mitotic asynchrony in response to acute
injury. Thus, different models are needed to specifically
investigate the effect of chronic airway damage and the in
vivo effect of VBP15 in other cells implicated in airway re-
modeling, including sub-epithelial fibroblasts and airway
smooth muscle. In addition, we cannot make any
conclusions about the potencies nor the physiological
relevance of the concentrations used for VBP15 versus
dexamethasone. Lastly, in evaluating the implications of
the present study, it must be emphasized that our obser-
vations pertain to studies conducted in an in vitro human
airway model lacking inflammatory cells. Therefore, the
extent to which these observations relate to the human
condition is open to debate.
Conclusions
In summary, VBP15 improves mitotic asynchrony and
injury-induced pro-inflammatory and fibrogenic responses
in asthmatic airway epithelial cultures with efficacy
comparable to traditional glucocorticoids. Together with
our prior in vivo data and the predicted superior side
effect profiles, VBP15 holds potential for treatment of
asthma and other respiratory conditions.
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